David S. Ettinger

David S. Ettinger's AcademicInfluence.com Rankings

David S. Ettinger

Medical

#2016

World Rank

#2406

Historical Rank

Oncology

#108

World Rank

#112

Historical Rank

medical Degrees

David S. Ettinger

Philosophy

#5920

World Rank

#8855

Historical Rank

Logic

#3129

World Rank

#4244

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is David S. Ettinger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David S. Ettinger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Non-small cell lung cancer clinical practice guidelines in oncology. (2006) (1010)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. (1989) (885)
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (2017) (805)
American Cancer Society lung cancer screening guidelines (2013) (638)
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) (623)
Multidisciplinary management of lung cancer. (2004) (573)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. (2019) (490)
Sequences of taxol and cisplatin: a phase I and pharmacologic study. (1991) (427)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (411)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. (2018) (411)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. (2016) (382)
Non-Small Cell Lung Cancer, Version 6.2015. (2015) (373)
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. (1992) (358)
A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. (1986) (331)
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (327)
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. (1986) (320)
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (313)
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. (1993) (298)
Non-small cell lung cancer. (2012) (277)
Non-small cell lung cancer. Clinical practice guidelines in oncology. (2004) (269)
Small cell lung cancer. (2008) (248)
Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. (2006) (245)
Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors (2018) (236)
Non-small cell lung cancer, version 2.2013. (2013) (234)
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. (1994) (224)
Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. (1985) (210)
Phase I and pharmacodynamic study of taxol in refractory acute leukemias. (1989) (207)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. (1993) (194)
Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung. A clinicopathologic study. (1979) (192)
Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program (2011) (189)
Phase I trial of taxol in patients with advanced cancer. (1987) (184)
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. (1997) (182)
Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. (1995) (181)
Variable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implications. (1978) (181)
Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. (1984) (169)
Staging and prognostic factors in small cell carcinoma of the lung. (1983) (167)
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. (2004) (164)
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. (2005) (163)
Senior adult oncology clinical practice guidelines in oncology. (2012) (163)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. (2020) (158)
Lung cancer screening: Clinical practice guidelines in oncology (2012) (154)
Non-small cell lung cancer, version 1.2015. (2014) (154)
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. (1996) (151)
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
Metastatic non-small cell lung cancer (1993) (146)
Ifosfamide in the treatment of non-small cell lung cancer. (1989) (132)
Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01 (2002) (129)
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. (1987) (129)
NCCN Guidelines Insights: Antiemesis, Version 2.2017. (2017) (123)
Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer (2013) (118)
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. (2010) (117)
Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. (2018) (116)
Phase I and pharmacologic study of topotecan in patients with impaired renal function. (1996) (115)
Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. (2005) (112)
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer (2020) (111)
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. (2007) (110)
Primary small cell carcinoma of the skin (1980) (108)
Targeted therapy for non-small-cell lung cancer: past, present and future (2013) (106)
The course of nausea and vomiting after high-dose cyclophosphamide. (1982) (106)
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. (2015) (106)
The use of chemotherapy in soft-tissue sarcomas. (2002) (105)
Non-small cell lung cancer. (2010) (103)
Antiemesis. Clinical Practice Guidelines in Oncology. (2004) (102)
Soft tissue sarcoma. (1999) (100)
Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. (1999) (99)
Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. (1997) (99)
A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. (1990) (97)
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. (1998) (92)
Antiemesis, version 2.2017 featured updates to the NCCN guidelines (2017) (92)
Long‐term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high‐risk, high‐grade, soft tissue sarcomas of the extremities and body wall (2010) (92)
NCCN: Non-small cell lung cancer. (2001) (89)
Novel antifolate drugs (2003) (89)
Use of isotopic immunoglobulin in therapy. (1980) (88)
Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. (1979) (88)
The Impact of Cancer Treatment on the Diets and Food Preferences of Patients Receiving Outpatient Treatment (2015) (83)
Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. (1992) (83)
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. (2005) (82)
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. (1996) (82)
Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort (2013) (81)
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma (2006) (79)
Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver. (1983) (79)
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy (2019) (79)
Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90‐15 (1995) (79)
Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment. (1980) (76)
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. (2016) (76)
Important clinical pharmacologic considerations in the use of methadone in cancer patients. (1979) (76)
Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. (1982) (75)
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. (2019) (72)
Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry. (1981) (71)
The role of surgery in the management of selected patients with small-cell carcinoma of the lung. (1987) (71)
Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. (2002) (70)
Phase I study of N1, N11-diethylnorspermine in patients with non-small cell lung cancer (2002) (69)
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (69)
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer (2018) (68)
Elevated histaminase (diamine oxidase) activity in small-cell carcinoma of the lung. (1975) (68)
Changing face of small-cell lung cancer: real and artifact. (2006) (67)
A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas (2011) (66)
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. (1994) (64)
Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. (2006) (64)
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. (2019) (63)
5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. (1998) (62)
EST 2582 Phase II Trial of Cisplatin in Metastatic or Recurrent Thymoma (1993) (62)
Soft tissue sarcoma clinical practice guidelines in oncology. (2005) (61)
Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. (1993) (60)
Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. (2002) (56)
Ten years of progress in non-small cell lung cancer. (2012) (55)
Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. (2002) (54)
Thymomas and thymic carcinomas (2013) (54)
Radiotherapy patterns of care study in lung carcinoma. (2003) (54)
Long-term survivors of small cell carcinoma of the lung. (1985) (53)
Management of small cell carcinoma of the lung. Therapy, staging, and biochemical markers (1976) (53)
NCCN Task Force Report: mTOR inhibition in solid tumors. (2008) (52)
Molecular Profiling of Malignant Pleural Effusion in Metastatic Non‐Small‐Cell Lung Carcinoma. The Effect of Preanalytical Factors (2017) (52)
NCCN antiemesis practice guidelines. (1997) (52)
Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. (1982) (51)
Hyperphosphatemia, hypocalcemia, and transient renal failure. Results of cytotoxic treatment of acute lymphoblastic leukemia. (1978) (51)
Lung cancer screening. (2003) (50)
Intensive induction therapy for small cell carcinoma of the lung. (1979) (50)
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. (2013) (50)
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. (2005) (49)
Biological markers for breast carcinoma (1984) (49)
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. (1993) (48)
'Sarcoidosis' and sarcoid-like lesions. Their occurrence after cytotoxic and radiation therapy of testis cancer. (1981) (48)
Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer (2004) (48)
5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting (1998) (47)
A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. (1991) (45)
Chemotherapy for lung cancer: the state of the art in 2009 (2009) (44)
The clinical significance of variant-morphology small-cell carcinoma of the lung. (1990) (44)
Overview and state of the art in the management of lung cancer. (2004) (44)
Biological markers and small cell carcinoma of the lung. A clinical evaluation of urinary ribonucleosides (1982) (44)
Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. (2005) (42)
Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors (2013) (42)
Evaluation of new drugs in untreated patients with small-cell lung cancer: its time has come. (1990) (42)
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. (2012) (41)
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. (1986) (41)
Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. (1981) (40)
New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. (2001) (40)
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. (1990) (40)
Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? (2002) (40)
NCCN Clinical Practice Guidelines Occult primary. (2011) (40)
Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. (1992) (40)
Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. (1986) (40)
Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP‐16 in small‐cell carcinoma of the lung (1982) (39)
Radiotherapy Patterns of Care Study in Lung Carcinoma (2003) (39)
Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapy (1985) (39)
Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. (1999) (38)
Overview of paclitaxel (Taxol) in advanced lung cancer. (1993) (37)
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). (1990) (36)
Molecular alterations in non-small cell lung carcinomas of the young. (2014) (35)
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data (2004) (35)
Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study. (1987) (35)
MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study (2017) (35)
Update: NCCN non-small cell lung cancer clinical practice guidelines. (2004) (34)
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study. (1987) (34)
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. (1995) (34)
Phase II trial of carboplatin in non-small cell lung cancer. (1986) (33)
Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung. (1978) (33)
A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). (2006) (32)
Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? (2005) (32)
Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. (2005) (31)
Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. (1995) (31)
A double‐blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy (1996) (30)
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. (1989) (30)
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors (2008) (30)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study (2010) (29)
A new biomarker in monitoring breast cancer: CA 549. (1988) (29)
Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report (2014) (28)
Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report (1991) (28)
Lung Cancer and Other Pulmonary Neoplasms (2012) (27)
Kaposi's sarcoma associated with multiple myeloma. (1975) (27)
Multimodality cisplatin treatment in nonresectable alpha‐fetoprotein‐positive hepatoma (1991) (27)
A Phase II study of all‐trans‐retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma (1998) (26)
Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. (1990) (25)
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. (2012) (25)
Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. (2010) (23)
Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? (2007) (23)
Quantitative gas-liquid chromatography of neutral sugars in human serum glycoproteins. Fucose, mannose, and galactose as predictors in ovarian and small cell lung carcinoma. (1979) (23)
Multiple biologic markers in the monitoring of treatment for patients with small cell carcinoma of the lung: The use of serial levels of plasma cea and serum carbohydrates (1981) (22)
Oral Levonantradol in the Treatment of Chemotherapy‐Induced Emesis: Preliminary Observations (1981) (22)
Occult primary, version 3.2014; Featured updates to the NCCN guidelines (2014) (22)
Small cell lung cancer clinical practice guidelines in oncology. (2006) (22)
RTOG 0017: A Phase I Trial of Concurrent Gemcitabine/Carboplatin or Gemcitabine/Paclitaxel and Radiation Therapy (“Ping-Pong Trial”) Followed By Adjuvant Chemotherapy for Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-small Cell Lung Cancer (2009) (22)
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. (2009) (21)
The role of carboplatin in the treatment of small-cell lung cancer. (1998) (21)
Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma. (1991) (20)
The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. (1981) (20)
Reye's syndrome in the adult: case report and review of the literature. (1983) (20)
Extensive-stage small-cell lung cancer. (2003) (19)
Monitoring breast cancer with CA 549. (1988) (19)
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer (2014) (19)
Managing acquired resistance in EGFR-mutated non-small cell lung cancer. (2015) (19)
The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update. (1995) (19)
Pregnancy following chemotherapy for an ovarian immature embryonal teratoma. (1979) (19)
Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: a case report. (1979) (19)
Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer (2011) (19)
NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. (2015) (19)
Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). (2002) (18)
Emerging profile of cetuximab in non-small cell lung cancer. (2010) (18)
Occult primary. (2008) (18)
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trial. (1999) (18)
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. (2022) (18)
JNCCN NCCN Task Force Report : Optimal Management of Patients with Gastrointestinal Stromal Tumor ( GIST ) — Update of the NCCN Clinical Practice Guidelines (2007) (17)
Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers. (1984) (17)
Tumor Localization of Radio-Labeled Antibodies (1980) (17)
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579). (1984) (17)
Gastric carcinoma 16 years after gastric lymphoma irradiation. (1977) (17)
Double‐Blind Multiple‐Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperazine (1984) (17)
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687) (1998) (16)
New methods applied to the analysis and treatment of ovarian cancer. (1978) (16)
Carboplatin in the Treatment of Small Cell Lung Cancer (1998) (16)
Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast. (1979) (16)
Taxol in the treatment of lung cancer. (1993) (16)
Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer (2004) (15)
Occult primary, version 3.2014. (2014) (15)
Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings (2009) (15)
Antiemesis clinical practice guidelines in oncology. (2004) (15)
A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy (2008) (14)
A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. (1986) (14)
NCCN Roundtable: What Are the Characteristics of an Optimal Clinical Practice Guideline? (2015) (14)
Tissue Is the Issue: Is Endoscopic Ultrasonography with or without Fine-Needle Aspiration Biopsy in the Staging of Non-Small-Cell Lung Cancer an Advance? (1997) (14)
Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study. (1989) (14)
Phase I study of N-methylformamide in patients with advanced cancer. (1985) (14)
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. (1988) (14)
RTOG 9705, a phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIA non-small cell lung cancer (NSCLC) patients — promising long term survival results (2003) (14)
Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer. (2018) (13)
Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study. (1980) (13)
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. (1995) (13)
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer. (2019) (13)
Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. (2002) (13)
Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. (1994) (13)
A feasibility study in the development of biological markers for ovarian cancer (1982) (13)
MA 09.08 Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1 (2017) (13)
Serum protein‐bound carbohydrates and small cell carcinoma of the lung correlations with extent of disease, tumor burden, survival, and clinical response categories (2006) (13)
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. (2019) (13)
Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). (1982) (12)
New drugs for treating small cell lung cancer. (1995) (12)
Non‐small cell lung cancer: Adjuvant and neo‐adjuvant chemotherapy (2007) (12)
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. (2018) (12)
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies. (1986) (12)
Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy. (1977) (12)
A phase I study of menogaril in patients with advanced cancer. (1987) (12)
Management of CNS metastases in small cell lung cancer: a consensus report (1989) (11)
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter (2007) (11)
NCCN practice guidelines for occult primary tumors (1998) (11)
A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. (2016) (10)
V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics (2018) (10)
Phase II trial of oral etoposide plus cisplatin in extensive stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study. (1994) (10)
Invasive aspergillosis. (1976) (10)
The integration of new therapies and radiation in the management of ovarian cancer (1981) (10)
Serial determinations of antiplatelet antibodies in a patient with Hodgkin's disease and autoimmune thrombocytopenia (1983) (10)
Pathologic complete response and survival outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: Long-term update of NRG Oncology RTOG 9514 and 0630. (2017) (10)
Response of plasma histaminase activity to heparin in normal subjects and in patients with small cell carcinoma of the lung. (1978) (9)
Multiple biological markers and breast carcinoma: A preliminary study in the detection of recurrent disease after primary therapy (1981) (9)
Biological markers as an aid in the clinical management of patients with liver metastases (1982) (9)
Concurrent radiochemotherapy in advanced breast cancer (1983) (9)
Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival (2015) (8)
Radiotherapy (RT) patterns of care study (PCS) in lung carcinoma (2002) (8)
Single-agent paclitaxel in the treatment of small cell lung cancer. (1996) (8)
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. (1999) (7)
Phase I and pharmacokinetic study of hepsulfam (NSC 329680). (1991) (7)
Impact of a Non‐small Cell Lung Cancer Educational Program for Interdisciplinary Teams (2017) (7)
Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update. (2016) (7)
Advances in Iodine 131-labeled antiferritin immunoglobulin cancer therapy (1982) (7)
Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity. (1981) (7)
Pemetrexed (Alimta): a new antifolate for non-small-cell lung cancer. (2002) (7)
Overview of ifosfamide in small cell lung cancer. (1992) (7)
Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. (1998) (7)
Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study. (1985) (7)
Non-small cell lung cancer treatment-related bone marrow toxicities. (2005) (6)
NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
Sputum cytologic diagnosis of Hodgkin's disease involving the lung. (1980) (6)
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
Malignant pleural mesothelioma. (2015) (6)
Thymic malignancies. (2010) (6)
International Consensus Panel Recommendations for the diagnosis of bone metastases (METS) from lung cancer (LC) (2008) (6)
Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High-Grade Soft-Tissue Sarcoma: The Johns Hopkins Experience (2017) (6)
Hexamethylene bisacetamide-induced cutaneous vasculitis. (1987) (6)
Phase II study of recombinant beta interferon in patients with advanced non-small-cell lung carcinoma. (1988) (5)
An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma. (1994) (5)
Alternating multiagent chemotherapy for advanced ovarian cancer (1983) (5)
Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study. (1985) (5)
The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. (2017) (5)
Ip immunotherapy and chemotherapy in advanced epithelial ovarian cancer. (1982) (5)
Timed‐sequential high‐dose cyclophosphamide and vincristine in the treatment of multiple myeloma (1994) (5)
A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics (2004) (5)
37 Docetaxel and cisplatin combination in patients with non-small cell lung cancer (NSCLC): A multicenter phase il trial (1997) (5)
Multimodality treatment of patients with advanced ovarian carcinoma. (1982) (5)
Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally‐advanced or advanced thymic epithelial tumors (2020) (5)
Nonsegmental ventilation-perfusion scintigraphy mismatch after radiation therapy. (1999) (5)
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. (2019) (5)
Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study. (1984) (5)
Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. (2010) (5)
Phase II Studies (1990) (5)
Toxicities in a phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239) (2007) (5)
6547 POSTER SNS-595: Preliminary results of 2 phase 2 second line studies in lung cancer (2007) (4)
Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer. (1990) (4)
Clinical and pharmacologic reappraisal of dichloromethotrexate. (1988) (4)
A randomized phase II study of m‐AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non‐small cell broncliogenic carcinoma: An Eastern Cooperative Group Study (1983) (4)
Management of bone metastases from lung cancer: Consensus recommendations from an international panel (2008) (4)
A phase II study of bisantrene in advanced refractory breast cancer: An Eastern Cooperative Oncology Group pilot study (1985) (4)
Doxorubicin, vincristine, and cis-diamminedichloroplatinum (II) therapy in patients with advanced breast cancer. (1981) (4)
Gemcitabine + ALIMTA™ in advanced non-small cell lung cancer (NSCLC): Why this regimen? (2000) (4)
New frontiers in the treatment of lung cancer. (1985) (4)
Patterns of care survey (PCS) in locally advanced non-small cell lung cancer (LA-NSCLC) and limited small cell lung cancer (LD-SCLC): how well does current practice follow the literature? (2003) (4)
Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer (RTOG 97-05) (2001) (3)
JNCCN NCCN Task Force Report : PET / CT Scanning in Cancer (2007) (3)
Lung cancer screening: has its time come? (2014) (3)
An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies. (2005) (3)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: (2011) (3)
Benign breast disorders: a symptomatic approach. (1987) (3)
Multisystem immune-related adverse events from anti-PD-1/PD-L1 in patients with lung cancer: Incidence, clinical patterns, management, and outcomes. (2019) (3)
Chronic radiation enteritis complicating non-Hodgkin's lymphoma. (1977) (3)
Lung cancer and family-centered concerns (2019) (3)
Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. (1986) (3)
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy. (2021) (3)
Multimodality cisplatin treatment in nonresectable afp positive hepatoma: Preliminary results (1989) (3)
Patterns of First Failure in a Phase II Study of Accelerated High Dose Thoracic Radiation Therapy (TRT) with Concurrent Chemotherapy for Limited Small-cell Lung Cancer (LSCLC): Radiation Therapy Oncology Group (RTOG) 0239 (2009) (3)
Benign breast disease. Diagnosis and treatment. (1977) (3)
Randomized chemoradiation for patients with locally advanced inoperable non-small cell lung cancer (NSCLC): Long-term follow-up of RTOG 92-04 (2000) (3)
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals (2019) (3)
Combined chemoradiation therapy for limited-stage small-cell lung cancer. (1999) (3)
377 Tolerability and limited activity of perifosine in patients with advanced soft tissue sarcoma (STS): a multi-center phase 2 consortium (P2C) study (2004) (3)
Tumor cell origin of histaminase activity in ascites fluid from patients with ovarian carcinoma (1980) (3)
Ifosfamide in the treatment of small cell lung cancer. (1996) (3)
Occult primary cancer clinical practice guidelines. (2005) (2)
Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586). (2000) (2)
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer (1990) (2)
A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study (2005) (2)
Gemcitabine-containing regimens in non-small cell lung cancer: are these standard therapies or not? (2000) (2)
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC (2021) (2)
Dual inhibition of the epidermal growth factor receptor (EGFR) pathway with the combination of cetuximab and erlotinib: A phase I study in patients with advanced solid malignancies (2007) (2)
Managing the patient with borderline resectable lung cancer. (2010) (2)
Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. (2023) (2)
Antiemetic effect of dexamethasone. (1984) (2)
EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN) (2022) (2)
New drugs in the treatment of non-small cell lung cancer (1991) (2)
Integrated ambulatory care services in oncology. (1992) (2)
Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group RTOG (2003) (2)
Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330 (2012) (2)
Molecular Alterations in Pulmonary Adenocarcinoma of African Americans. (2019) (2)
Combined-modality treatment for stage IIIa (n2) non-small cell lung cancer: a national cancer institute intergroup study (2009) (1)
NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology (2014) (1)
Supportive care in cancer therapy (2009) (1)
Medical oncology committee (2001) (1)
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy (2022) (1)
Sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy. (1987) (1)
RTOG 0330: A pilot phase II study of preoperative radiation therapy/thalidomide for low-grade primary soft tissue sarcoma or preoperative MAID/thalidomide/radiation therapy for high/intermediate grade primary soft tissue sarcoma of the extremity or body wall (2008) (1)
EGFR and C-Kit immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the WHO: An Eastern Cooperative Oncology Group Study. (2004) (1)
Erratum: Smoking status and survival in the national comprehensive cancer network nonsmall cell lung cancer cohort (Cancer (doi: 10.1002/cncr.27824)) (2013) (1)
NCCN Lung Cancer Screening , Version 3 . 2018 Clinical Practice Guidelines in Oncology (2018) (1)
Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (2011) (1)
Abnormal fatty acid breath tests in cancer patients, with nutritional correlation (1982) (1)
Use of Isotopie Immunoglobulin in Therapy1 (2006) (1)
Radiolabeled antibodies in the treatment of primary hepatic malignancies (1982) (1)
Comprehensive modeling of longitudinal circulating tumor DNA dynamics to predict clinical response to first-line immunotherapy and chemoimmunotherapy in advanced non-small cell lung cancer. (2020) (1)
E06-03: Management of bone metastasis - role of bisphosphonates (2007) (1)
Combination chemotherapy of small cell carcinoma of the lung (1975) (1)
Advanced pulmonary carcinoid (APC): 20-year experience at Johns Hopkins (JH). (2013) (1)
Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma. (1987) (1)
Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC) (2018) (1)
Fatty acid breath test values in the malabsorption range in cancer patients. (1982) (1)
Chemotherapy and treatment scheduling: the Johns Hopkins Oncology Center Outpatient Department. (1993) (1)
NCCN Antiemesis Panel Members (2010) (1)
MA07.05 Survivors from Anti-PD-(L)1 Immunotherapy in NSCLC: Clinical Features, Survival Outcomes and Long-term Toxicities (2021) (1)
Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation (2022) (1)
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study (1989) (1)
Levonantradol, a synthetic cannabinoid with potential usefulness as an antiemetic in chemotherapy-induced emesis (1981) (1)
Erratum: NCCN occult primary cancer guidelines (JNCCN Journal of the National Compehensive cancer Network (March 2005) 3 (214-233)) (2005) (1)
Taxol (T): An active new drug in ovarian epithelial cancer (OVCA) (1989) (1)
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade (2022) (1)
Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy. (2018) (1)
Prognostic factors by histologic subtype in stage IV non-small cell lung cancer (NSCLC): A population-based survival analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program (1988-2003). (2016) (1)
Patients' guide to lung cancer (2011) (1)
NCCN practice guidelines for neuroendocrine tumors (1999) (1)
Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. (2016) (1)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Lung Cancer Committee. (2001) (1)
Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer. (2000) (1)
Erratum: The role of topotecan in the treatment of small cell lung cancer (Oncologist (1998) 3 (11-14)) (1998) (0)
Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1 (2006) (0)
Discussion: Lung cancer (1996) (0)
Lung cancer committee (2001) (0)
Comprar Supportive Care in Cancer Therapy | Ettinger, David S. | 9781588299413 | Springer (2008) (0)
The final dilemma. End-of-life treatment decisions. (1998) (0)
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
Thirty Years Later: We've Only Just Begun (2006) (0)
Multimodality treatment of stage 3 ovarian cancer (1981) (0)
High dose methotrexate (HDMTX) with citrovorum factor (CF) rescue in inoperable non-oat cell bronchogenic carcinoma (1979) (0)
First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. (2010) (0)
Recent Advances in the Management of Chemotherapy-induced Nausea and Vomiting: A Case Study Compendium. (2010) (0)
Molecular Alterations in Non Small Cell Lung Cancers of the Young (2013) (0)
Immune checkpoint inhibition in elderly non-small cell lung cancer patients. (2018) (0)
Abstract 1617: Sex-specific genomic determinants of response to immunotherapy (2021) (0)
Lung Metastases (2020) (0)
Discussion: Neurotoxicity of ifosfamide therapy (1996) (0)
CERTIFIED FOR PUBLICATION COURT OF APPEAL, FOURTH APPELLATE DISTRICT DIVISION ONE STATE OF CALIFORNIA (2004) (0)
Malignant: Primary small cell carcinoma of skin (1981) (0)
Continue NCCN Clinical Practice Guidelines in Oncology TM Non-Small Cell Lung Cancer (0)
Acute esophagitis correlated with irradiated volume in a Phase II Study of Accelerated High Dose Thoracic Radiation Therapy (TRT) with Concurrent Chemotherapy for Limited Small Cell Lung Cancer (LSCLC) (RTOG 0239): P1-205 (2007) (0)
296 A comprehensive clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer (2021) (0)
Corrigendum to “Emerging profile of cetuximab in non-small cell lung cancer” [Lung Cancer 68 (2010) 332–337] (2010) (0)
Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy. (2019) (0)
Occult primary: Clinical practice guidelines in oncology (2008) (0)
Concomitant doxorubicin and irradiation for additive cytotoxicity in adrenocortical carcinoma (1984) (0)
Response of plasma histamine activity (PHA) to heparin in patients with small cell carcinoma of the lung (SCC) (1977) (0)
Etoposide and Mitomycin in the Treatment of Non‐Small‐Cell Lung Cancer: A Phase I‐II Evaluation (1991) (0)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Sarcoma Committee. (2001) (0)
P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial (2017) (0)
The Role of Garboplatin in the Treatment of Small-Cell Lung Cancer (1998) (0)
Multimodality approach to stage III NSCLC: Current state of knowledge (2006) (0)
P-171 A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study (2003) (0)
AntiemesisPractice Guidelines in Oncology TM (2009) (0)
NCCN Guidelines TM Version 2 . 2011 Table of Contents Non-Small Cell Lung Cancer Clinical Trials : Categories of Evidence and Consensus : (2001) (0)
QIM21-090: The Expanding Role of an Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events (2021) (0)
A Phase I Trial of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Concurrent Radiation Therapy Followed by Consolidative Gemcitabine and Carboplatin for Inoperable Stage III Non-Small Cell Lung Cancer: An RTOG 0017 Study (2005) (0)
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC (2022) (0)
P-53 Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group (RTOG) protocol 9712 (2003) (0)
P-391 How dedicated Positron Emission Tomography-CT (PET-CT) affects the diagnostic and therapeutic approaches to patients managed by a Multimodality Thoracic Oncology Group (2005) (0)
Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1 (2006) (0)
P2.03a-010 A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC: Topic: Clinical Trials (2017) (0)
Abstract 27: Early dynamics in peripheral blood immune cell subsets and ctDNA are predictive of outcome to immunotherapy (2021) (0)
Lung Cancer ScreeningPractice Guidelines in Oncology (2012) (0)
Individualized therapy for nonsmall-cell lung cancer: A look at histology (2011) (0)
Abstract 1668: Longitudinal dynamics of circulating tumor DNA and plasma proteomics predict clinical outcomes to immunotherapy in non-small cell lung cancer (2021) (0)
Abstract 4483: Distinct spatial distribution patterns of ALK-inhibitor naïve versus ALK-inhibitor treated ALK-positive NSCLC brain metastases (2023) (0)
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer. (2022) (0)
Combination chemotherapy with cyclophosphamide (C), adriamycin (A), and mitomycin-C (M) in advanced non-small cell bronchogenic carcinoma (NSCB) (1981) (0)
Evaluation of vinblastine and bleomycin as second-line therapy in advanced ovarian carcinoma (1984) (0)
Treatment simulation in localized small cell cancer: a new approach to combined radiotherapy + chemotherapy (1978) (0)
Second-generation inhibitors of fatty acid synthase for lung cancer treatment (2007) (0)
Evaluation of alternating chemotherapy in patients with small cell lung cancer - a commentary (1991) (0)
Evaluating the Role of Interdigitated Neoadjuvant Chemotherapy and Radiation in the Management of High Grade Soft Tissue Sarcoma: A Retrospective Study of the Johns Hopkins Experience (2011) (0)
Abstract 538: Liquid biopsy approaches for determining pathologic response to neoadjuvant immunotherapy in esophageal cancer (2021) (0)
9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial (2009) (0)
Gemcitabine (G) and vinorelbine (V) in patients (pts) with recurrent advanced non-small cell lung cancer (NSCLC): Sequence of administration matters. (2006) (0)
Chemotherapy for Advanced NSCLC (2003) (0)
Non-small cell lung cancer. (2008) (0)
Antroquinonol to block Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells. (2015) (0)
Lung and mediastinum: Editorial overview (1993) (0)
P3.01-70 Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer (2018) (0)
Combined Modality Treatment of Small-Cell Lung Cancer (2003) (0)
P-578 A phase I trial of gemcitabine, carboplatin or gemcitabine paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study (2005) (0)
The clinical significance of variant morphology small cell carcinoma of the lung (1989) (0)
Gemcitabine plus radiation therapy in the treatment of locally advanced non small-cell lung cancer. (2000) (0)
NEUROENDOCRINE TUMORS (2007) (0)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology (2012) (0)
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. (2001) (0)
Abstract of Satellite Symposia Speakers Bristol-Myers Squibb Company Sunday, June 26, 1994 Current perspectives in the treatment of small cell lung cancerNew Drugs for treating small cell lung cancer (1994) (0)
Endodermal sinus tumor. Report of a case with remission following chemotherapy. (1977) (0)
RADIATION THERAPY ONCOLOGY GROUP RTOG S-0120 A RANDOMIZED PHASE I/II STUDY OF PREOPERATIVE RADIOTHERAPY WITH/WITHOUT SUGEN 5416 (NSC #696819; A TK INHIBITOR ANTI-ANGIOGENESIS COMPOUND) IN THE MANAGEMENT OF LOW TO INTERMEDIATE GRADE SOFT TISSUE SARCOMA OF THE TRUNK OR EXTREMITY (2002) (0)
ASTR scientific paper to be presentedNew methods applied to the analysis and treatment of ovarian cancer (1978) (0)
Nausea and vomiting with multi-day chemotherapy (2010) (0)
Systemic and combined modality therapy for lung cancer. (1990) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David S. Ettinger?

David S. Ettinger is affiliated with the following schools:

David S. Ettinger's Academic­Influence.com Rankings

Why Is David S. Ettinger Influential?

David S. Ettinger's Published Works

Published Works

What Schools Are Affiliated With David S. Ettinger?

David S. Ettinger's AcademicInfluence.com Rankings